ZLNA Zelluna ASA

1.518USD14.70 NOK · OSL-4.85%Mkt Cap: 45.32M USDP/E: —

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment…

Key Statistics

Company
Market Cap45.32M USD
Enterprise Value39.17M USD
Revenue (TTM)39.85K USD
Gross Profit39.85K USD
Net Income (TTM)-14.53M USD
Revenue/Share0.0015 USD
Last Price1.518 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees15
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013524942
Valuation
P/E (Trailing)—
P/E (Forward)-5.65
PEG—
EV/EBITDA-3.81
EV/Revenue982.84
P/S1137.17
P/B5.08
EPS (TTM)-0.41 USD
EPS (Forward)-0.27 USD
52W Range
0.846924% of range3.696
52W High3.696 USD
52W Low0.8469 USD
Profitability
Gross Margin100.00%
Oper. Margin-26637.31%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-46.84%
ROA-45.67%
ROIC-48.05%
ROCE-46.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.38M USD
CapEx (TTM)37.06K USD
FCF Margin-14474.81%
FCF Yield-12.73%
Net Debt-6.15M USD
Net Debt/EBITDA0.60
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio7.49
Quick Ratio7.37
Book Value/Sh0.30 USD
Cash/Share0.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 1, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.86M
Float13.57M
Insiders40.60%
Institutions15.72%
Technical
SMA 501.924 (-21.1%)
SMA 2002.076 (-26.9%)
Beta—
S&P 52W Chg8.68%
Avg Vol (30d)31.05K
Avg Vol (10d)57.55K
Technical Indicators
RSI (14)31.8
MACD-1.0349
MACD Signal-0.9288
MACD Hist.-0.1061
BB Upper2.007 USD
BB Middle1.727 USD
BB Lower1.447 USD
BB Width32.47%
ATR (14)0.1073 USD
Vol Ratio (20d)0.32x

About Zelluna (OSL: ZLNA)

›

Zelluna (OSL: ZLNA) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.

The shares were at 14.70 NOK on 20 November 2026, up 65.2% over 52 weeks. Its 52-week range is 8.204 NOK to 35.80 NOK: the price is 58.9% below the high and 79.2% above the low.

Its market capitalisation is 438.95M NOK.

Zelluna reports return on equity of -46.8%.

It holds more cash than debt, a net cash position of 59.57M NOK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 February 2027.